These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 19327852)

  • 1. Do levosimendan have an adverse effect on platelet function?
    Kaptan K; Beyan C; Ifran A
    Int J Cardiol; 2010 Oct; 144(3):414-5. PubMed ID: 19327852
    [No Abstract]   [Full Text] [Related]  

  • 2. ST-segment elevation during levosimendan infusion.
    Barillà F; Giordano F; Jacomelli I; Pellicano M; Dominici T
    J Cardiovasc Med (Hagerstown); 2012 Jul; 13(7):454-6. PubMed ID: 22673026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [LEVOSIMENDAN--THE FIRST 10 YEARS IN CLINICAL PRACTICE].
    Rybka MM; Lobacheva GV
    Anesteziol Reanimatol; 2015; 60(5):80-4. PubMed ID: 26852586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Perioperative use of levosimendan: best practice in operative settings.
    Toller W; Algotsson L; Guarracino F; Hörmann C; Knotzer J; Lehmann A; Rajek A; Salmenperä M; Schirmer U; Tritapepe L; Weis F; Landoni G
    J Cardiothorac Vasc Anesth; 2013 Apr; 27(2):361-6. PubMed ID: 22658687
    [No Abstract]   [Full Text] [Related]  

  • 5. [Levosimendan. Clinical indications of a new vasoactive substance].
    Braun JP; Döpfmer U; Kastrup M; Roots I; Borges A; Schneider M; Dohmen P; Kox W; Spies C
    Anaesthesist; 2004 Feb; 53(2):163-7. PubMed ID: 14991194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Levosimendan: a new option in acute cardiac failure.
    Holley AD; Ziegenfuss M
    Emerg Med Australas; 2006; 18(5-6):505-9. PubMed ID: 17083641
    [No Abstract]   [Full Text] [Related]  

  • 7. Oral levosimendan in patients with severe chronic heart failure --the PERSIST study.
    Nieminen MS; Cleland JG; Eha J; Belenkov Y; Kivikko M; Põder P; Sarapohja T
    Eur J Heart Fail; 2008 Dec; 10(12):1246-54. PubMed ID: 18945637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Calcium sensitizer agents in heart failure therapy].
    Iwama Y; Takagi A
    Nihon Rinsho; 2007 May; 65 Suppl 5():61-5. PubMed ID: 17571366
    [No Abstract]   [Full Text] [Related]  

  • 9. [Levosimendan and dobutamine have a similar profile for potential risk for cardiac arrhythmias during 24-hour infusion in patients with acute decompensated heart failure].
    Tek M; Cavuşoğlu Y; Demirüstü C; Birdane A; Ünalır A; Görenek B; Göktekin Ö; Ata N
    Turk Kardiyol Dern Ars; 2010 Jul; 38(5):334-40. PubMed ID: 21200103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacodynamics and safety of a new calcium sensitizer, levosimendan, and its metabolites during an extended infusion in patients with severe heart failure.
    Kivikko M; Antila S; Eha J; Lehtonen L; Pentikäinen PJ
    J Clin Pharmacol; 2002 Jan; 42(1):43-51. PubMed ID: 11808823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can pulmonary artery hypertension be attributed to levosimendan? A problematic based on a patient's case.
    Tagarakis GI; Baddour AJ; Tsilimingas NB
    J Cardiovasc Med (Hagerstown); 2010 Jul; 11(7):552-3. PubMed ID: 20035233
    [No Abstract]   [Full Text] [Related]  

  • 12. Efficacy of intravenous levosimendan in patients with heart failure complicated by acute myocardial infarction.
    Jia Z; Guo M; Zhang YQ; Liang HQ; Zhang LY; Song Y
    Cardiology; 2014; 128(2):195-201. PubMed ID: 24751462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Therapy of acute decompensated heart failure with levosimendan].
    Müller K; Peters A; Zeus T; Hennersdorf M; Strauer BE
    Med Klin (Munich); 2006 Mar; 101 Suppl 1():119-22. PubMed ID: 16802535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Levosimendan for the treatment of acute heart failure syndromes: time to identify subpopulations of responding patients.
    Parissis JT; Farmakis D; Bistola V; Adamopoulos S; Kremastinos DT
    Am J Cardiol; 2007 Jan; 99(1):146-7. PubMed ID: 17196480
    [No Abstract]   [Full Text] [Related]  

  • 15. Repeated infusions of levosimendan: well tolerated and improves functional capacity in decompensated heart failure - a single-centre experience.
    Parle NM; Thomas MD; Dembo L; Best M; Driscoll GO
    Heart Lung Circ; 2008 Jun; 17(3):206-10. PubMed ID: 18242130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Levosimendan and platelet function.
    Kaptan K; Beyan C
    J Cardiothorac Vasc Anesth; 2010 Jun; 24(3):532. PubMed ID: 19632863
    [No Abstract]   [Full Text] [Related]  

  • 17. Rationale and design of a randomized, double-blind, placebo controlled multicenter trial to study efficacy, security, and long term effects of intermittent repeated levosimendan administration in patients with advanced heart failure: LAICA study.
    García-González MJ; de Mora-Martín M; López-Fernández S; López-Díaz J; Martínez-Sellés M; Romero-García J; Cordero M; Lara-Padrón A; Marrero-Rodríguez F; del Mar García-Saiz M; Aldea-Perona A;
    Cardiovasc Drugs Ther; 2013 Dec; 27(6):573-9. PubMed ID: 23887741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of acute cardiac failure by intracoronary administration of levosimendan.
    Caimmi PP; Kapetanakis EI; Beggino C; Molinari C; Giustini G; Crosio E; Reposo G; Micalizzi E; Vacca G; Grossini E
    J Cardiovasc Pharmacol; 2011 Sep; 58(3):246-53. PubMed ID: 21654504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and effectiveness of levosimendan in patients with predominant right heart failure.
    Poelzl G; Zwick RH; Grander W; Metzler B; Jonetzko P; Frick M; Ulmer H; Pachinger O; Roithinger FX
    Herz; 2008 Jul; 33(5):368-73. PubMed ID: 18773157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Levosimendan increases bleeding risk after heart valve surgery: a retrospective analysis of a randomized trial.
    Lahtinen P; Pitkänen O; Musialowicz T
    J Cardiothorac Vasc Anesth; 2014 Oct; 28(5):1238-42. PubMed ID: 25281042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.